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Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, affecting 9–18% of women in reproductive age that
causes hyperandrogenism and infertility due to dysfunctional follicular maturation and anovulation. The etiology of PCOS
is still poorly known, and information from experimental animal models may help improve current understanding of the
mechanisms of PCOS initiation and development. Therefore, we conducted a systematic review of currently available
methods for simulation of PCOS in experimental models, focusing on two main endocrine traits: ovarian morphology
changes and circulating levels of sex hormones and gonadotropins.
We searched the MEDLINE database for articles in English or Spanish published until October 2016. Of 933 studies
identified, 39 were included in the systematic review. One study compared interventions with androgens versus
estrogens, 18 used androgen-induced stimulation, 9 used estrogens or drugs with estrogen action, including endocrine
disruptors, to induce PCOS-like models, and 12 used miscellaneous interventions. Broad differences were found
among the studies concerning hormonal interventions, animal species, and developmental stage at the time of the
experiments, and most models resulted in ovarian morphology changes, mainly increases in the number of cystic and
antral follicles and decreases in the corpus luteum. Hyperandrogenism was produced by using androgens and other
drugs as the stimulatory agent. However, studies using drugs with estrogenic effect did not observe changes in
circulating androgens.
In conclusion, medium- or long-term testosterone administration in the pre- and postnatal periods performed best
for induction of a PCOS-like phenotype, in rhesus macaque and rat models respectively. In rats, postnatal exposure
to androgens results in reprogramming of the hypothalamic-pituitary-ovarian-axis. Thus, comparisons between
different intervention models may be useful to define the timing of reproductive PCOS phenotypes in experimental
animal models.
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Background
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine conditions, affecting 9–18% of
women of reproductive age, depending on diagnostic
criteria [1]. PCOS is characterized by at least two of the
three following criteria: clinical or biochemical hyperan-
drogenism, oligo/anovulation, and polycystic ovaries [2].
Clinically, these manifestations are associated with re-
duced fertility, due to dysfunctional follicular maturation
and consequent anovulation, and hyperandrogenism,
causing acne and hirsutism [3]. Both chronic anovula-
tion and androgen excess are linked to disturbed follicu-
logenesis, that is expressed by multiple cystic follicles
between 2 and 9 mm and increased ovarian volume in
women with PCOS [4].
Clinical PCOS may have its onset before or during
puberty [5]. Clinical studies have suggested that girls
with PCOS exhibit increased gonadotropin releasing
hormone (GnRH) pulse frequency, leading to excess
luteinizing hormone (LH) secretion. This causes prema-
ture acquisition of LH receptor expression by growing
ovarian follicles at excessively early stages, leading to
increased ovarian androgen production [6, 7] and, prob-
ably, to the arrested antral follicle development of PCOS
[8]. Indeed, this follicular arrest is consistent with the
polycystic ovary morphology found on ultrasound exam-
ination in human PCOS [2]. Moreover, PCOS-affected
ovaries exhibit an increase in the number of growing
preantral and antral follicles, which leads to antrum
expansion, increased granulosa cell degeneration, and
development of cystic follicles, with thin granulosa cell
walls and a thicker surrounding layer of theca cells [8].
Since Stein and Leventhal first described PCOS in the
mid-1930s [9], the search began to identify the etiologic
mechanisms associated with its development. Yet,
despite its prevalence and health impact, the etiology of
PCOS remains poorly understood. Even whether repro-
ductive hormone abnormalities are primary or secondary
remains enigmatic. Hypotheses for the origins of this
pathology include hormonal imbalances, genetic abnor-
malities, and lifestyle and environmental factors [3]. Due
to logistic and ethical limitations on human experimen-
tation, several animal models to simulate PCOS have
been developed in recent decades. These experimental
models can improve understanding of the pathophysi-
ology of PCOS and have the potential to support devel-
opment of innovative and curative treatments.
Within this context, the aim of this paper was to sys-
tematically review the available rodent and non-human
primate animal models of PCOS-like conditions and
summarize ovarian function and hormonal disturbances
linked to reproductive damage, as well as discuss the
advantages and possible limitations of applying these
models to human PCOS.
Methods
Search strategy and study selection
We performed a systematic review in accordance with the
PRISMA guidelines. Briefly, we searched the MEDLINE
database, via PubMed, for literature published in English
and Spanish until October 2016. The search strategy con-
sisted of the following Medical Subject Headings (MeSH):
“Animal Model” OR “Animal Models” OR “Model,
Animal” OR “Laboratory Animal Models” OR “Animal
Model, Laboratory” OR “Animal Models, Laboratory” OR
“Laboratory Animal Model” OR “Model, Laboratory
Animal” OR “Models, Laboratory Animal” OR “Experi-
mental Animal Models” OR “Animal Model, Experimental”
OR “Animal Models, Experimental” OR “Experimental
Animal Model” OR “Model, Experimental Animal” OR
“Models, Experimental Animal” OR Rodents OR Rodentias
OR Rodent OR Rat OR Rattus OR “Rattus norvegicus” OR
“Rats, Norway” OR “Rats, Laboratory” OR “Laboratory Rat”
OR “Laboratory Rats” OR “Rat, Laboratory” OR Mus OR
Mouse OR “Mus musculus” OR “Mice, House” OR
“House Mice” OR “Mouse, House” OR “House Mouse”
OR “Mus domesticus” OR “domesticus, Mus” OR “Mus
musculus domesticus” OR “domesticus, Mus musculus”
OR “musculus domesticus, Mus” OR “Mice, Laboratory”
OR “Laboratory Mice” OR “Mouse, Laboratory” OR
“Laboratory Mouse” OR “Mouse, Swiss” OR “Swiss
Mouse” OR “Swiss Mice” OR “Mice, Swiss” OR AND
“Ovary Syndrome, Polycystic” OR “Syndrome, Polycystic
Ovary” OR “Stein-Leventhal Syndrome” OR “Stein
Leventhal Syndrome” OR “Syndrome, Stein-Leventhal”
OR “Sclerocystic Ovarian Degeneration” OR “Ovarian
Degeneration, Sclerocystic” OR “Sclerocystic Ovary
Syndrome” OR “Polycystic Ovarian Syndrome” OR “Ovarian
Syndrome, Polycystic” OR “Polycystic Ovary Syndrome 1”
OR “Sclerocystic Ovaries” OR “Ovary, Sclerocystic” OR
“Sclerocystic Ovary”.
The selection criteria were as follows: experimental
studies of interventions in female rats, mice, guinea pigs,
or non-human primates aiming to induce PCOS-like re-
productive characteristics, namely, follicles with cystic
appearance and altered serum testosterone levels. We
also performed a hand search of the reference lists of
full-text articles. Studies were excluded from the analysis
if the outcome was not induction of PCOS symptoms in
experimental animals and if reproductive outcomes were
nor described.
Data extraction
Two investigators (LP and RBR) independently reviewed
the titles and abstracts and selected articles for full-text
review. Disagreements were resolved by a third reviewer
(PMS) or by consensus discussion. The selected articles
were independently read in full to confirm eligibility and
extract data. The information extracted from each
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individual study was as follows: name of first author,
publication year, animal species, number of animals, age
at start and at intervention time, intervention type, ex-
perimental period, and three variables of interest: serum




A detailed flow diagram of the study selection process is
shown in Fig. 1. The primary search identified 933 arti-
cles. After title and abstract screening, 65 potentially eli-
gible studies were retrieved for full-text review. Of these,
26 were excluded: 21 did not meet the inclusion criteria;
3 were narrative reviews; and 2 were very old publica-
tions that could not be retrieved. Therefore, 39 studies
were included in the systematic review: 19 animal
models using androgen-induced stimulation [10–28]; 9
which employed estrogens and estrogen-like drugs to in-
duce a PCOS-like syndrome [27, 29–36]; and 12 using
other interventions [37–48].
Table 1 summarizes the characteristics of the studies
included in the systematic review that used androgens as
the stimulus to induce a PCOS-like phenotype. Most of
the studies used rodents (3 studied mice, 11 used rats)
and 5 used monkeys as the experimental model. Table 1
also shows that androgen induction was applied at dif-
ferent periods in the reported studies: short-term (up to
30 days of androgen induction) [12, 19, 20, 26, 27];
medium-term (30 to 90 days) [10, 11, 13–16, 21, 25];
and long-term (>90 days) [17, 22–24]. In addition,
interventions were applied to animals at distinct devel-
opmental stages, as described below.
Five studies described prenatal interventions and ob-
served the offspring at different periods of development
[10–13, 25]. Three of these studies used rats as the
experimental model [10–12], one utilized female mice
[13], and another used rhesus macaques [25]. Wu et al.
(2010) [10] and Yan et al. (2013) [12] used the Sprague–
Dawley rat strain for medium- and short-term induction,
respectively. Wu et al. (2010) [10] administered testos-
terone during gestation and dihydrotestosterone (DHT)
through 70 days after birth and found elevated testoster-
one levels, but no ovarian changes. Yan et al. (2013) [12]
administered DHT during gestation and found only
cystic and atretic follicles. Caldwell et al. (2014) [13]
administered DHT during gestation plus DHT or dehy-
droepiandrosterone (DHEA) as postnatal treatment in
female mice, and observed cystic and atretic follicles
only. Similar findings were reported by Tyndall et al.
(2012) [11], who administered pre- and postnatal treat-
ment with testosterone propionate for 25–90 days and
observed cystic follicles as the only change. Finally,
Abbott et al. (1998) [25] administered testosterone pro-
pionate for 15–88 days, starting at various gestational
ages, and found consistent reproductive features similar
to clinical PCOS in female rhesus macaque offspring,
such as increased serum testosterone and LH levels,
Fig. 1 Animal models using androgen-induced stimulation
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Table 1 Animal models using androgen-induced stimulation
Author, year [reference] Animal N Intervention and duration Studied variables Results
Intervention period: Fetal
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lower follicle stimulating hormone (FSH) levels, and
ovaries containing multiples cystic follicles.
Eight studies described postnatal interventions and ob-
served offspring at different periods of development.
Seven of these studies used female rats [15–18, 26, 27]
and one used female mice [14]. While most studies used
testosterone or DHT, only two studies administered
DHEA to induce ovarian dysfunction [18, 28]. Misugi et
al. (2006) [18] observed both cystic/atretic follicles and
high testosterone levels in response to DHEA stimula-
tion. Paixão et al. (2015) used a single equine chorionic
gonadotropin (eCG) dose to induce initial follicular
recruitment in prepubertal rats and added DHEA to
generate ovarian dysfunction. These animals presented
greater testosterone levels and higher number of, and
larger-sized, primary and secondary follicles as com-
pared with the control group [28].
Ota et al. (1983) [17] also found cystic follicles and ele-
vated testosterone levels after administration of testoster-
one propionate injections to Wistar rats. Ongaro et al.
(2015) [26] administered a single dose of testosterone pro-
pionate to 5-day-old female Sprague–Dawley rats, and
found no differences in testosterone or estradiol levels at
30 and 60 days. Cystic follicles were observed only in
60-day-old animals. Marcondes et al. (2015) [27] adminis-
tered a single dose of testosterone propionate to 0-to-2-
day-old female Wistar rats. Increased testosterone levels,
cystic follicles, and absence of corpora lutea were found at
90–94 days of age. Manneras et al. (2007) [16] adminis-
tered DHT to the same rat strain and found cystic folli-
cles, but no testosterone changes. Unlike Ota et al. (1983)
[17], who conducted a long-term intervention, the study
by Manneras et al. (2007) [16] had a medium-term
observation period. Both Zhai et al. (2012) [15] and van
Houten et al. (2012) [14] also conducted experiments of
intermediate duration. These two studies found cystic
follicles and increased androgen levels, despite using
different animals and different types of androgens as inter-
vention. While van Houten et al. (2012) [14] observed
female mice under DHT treatment, Zhai et al. (2012) [15]
studied female Sprague–Dawley rats receiving testoster-
one plus a high-fat diet.
Two studies described postnatal interventions and ob-
served the offspring at different periods of development
[19, 20]. In these studies, DHEA was administered for
20 days to female mice [19] and to female rats [20].
One study did not find any changes [20], whereas the
other reported cystic follicles and increased testoster-
one levels [19].
The four available studies of adult animals were per-
formed on non-human primates [21–24]. Tang et al.
(2012) [21] observed cystic follicles and increased testos-
terone levels after medium-term treatment with testoster-
one propionate plus hCG injection. The other three
studies used long-term treatment with androgens [22–24].
McGee et al. (2014) [22] found antral follicles and high
levels of testosterone after treatment with testosterone
plus a high-fat diet. One study of androstenedione inter-
vention [24] found increased testosterone levels and
atretic follicles but no cystic or antral follicles. Faiman et
al. (1988) [23], using testosterone as the intervention, did
not observe any changes in hormone levels or ovarian
morphology.
Animal models using drugs with estrogenic effects
Table 2 shows the characteristics of studies that used es-
trogen or drugs with estrogenic effects to induce a
PCOS-like phenotype in experimental animals. These
studies used acute estrogen treatment, lasting hours to
days [27, 29–31, 34, 35], and short-term interventions,
lasting 2 to 30 days [32, 33, 36]. All models used ro-
dents, at distinct developmental stages: eight studies
used rats and one used guinea pigs.
Four studies described the use of drugs with estrogen
action during the postnatal and pubertal periods, at dif-
ferent time points of observation. One [29] used the
Sprague–Dawley rat strain, while three [27, 30, 31] used
female Wistar rats. In all four studies, the intervention
consisted of a single dose of estradiol valerate and cystic
follicles were observed after treatment. Regarding sex
hormone levels, Cruz et al. (2012) [29] and Marcondes
et al. (2015) [27] failed to demonstratehigh androgen
levels, while the other two studies [30, 31] did not report
blood androgen concentrations.
Table 1 Animal models using androgen-induced stimulation (Continued)

















T testosterone, E2 estradiol, LH luteinizing hormone, FSH follicle-stimulating hormone, CL corpus luteum, PA prenatal androgenization, DHT dihydrotestosterone,
DHEA dehydroepiandrosterone, HFD high-fat diet; ↑: increase; ↓ decrease; = equal; - -: not available
Paixão et al. Reproductive Biology and Endocrinology  (2017) 15:12 Page 5 of 11
Four studies described interventions with estradiol
valerate or 17β-estradiol in adult animals, with different
treatment periods. Three of the studies used female
Wistar rats [33, 35, 36], while one [34] used guinea pigs
as the model organism.
Fernández et al. (2010) [32] exposed female Sprague–
Dawley rats to bisphenol A (BPA) for 10 days. This study
was able to show the main reproductive outcomes
expected for an animal model of PCOS, such as the
presence of cystic and atretic follicles alongside elevated
testosterone levels.
Hemmings et al. (1983) [35] administered a single dose
of estradiol valerate, whereas Quandt et al. (1993) [34]
used estradiol injections over 2 days. Although these stud-
ies used different rodent models, both detected the pres-
ence of cystic follicles and unchanged androgen levels.
Two of the studies [33, 36] used distinct inter-
ventions and durations in the same animal strain.
Zangeneh et al. (2011) [33] administered a single dose of
estradiol valerate plus cold stress induction, while
McCarthy and Brawer (1990) [36] used implanted estra-
diol pellets and an observation period of 50 consecutive
days. Both studies found cystic follicles in the ovaries, but
did not measure blood androgen levels.
Animal models using miscellaneous interventions
Table 3 presents the characteristics of studies that used
interventions other than androgen and estrogen treat-
ment to induce PCOS-like phenotypes. These miscellan-
eous interventions included transgenic animals [37–39]
or specific strains [46], drugs that stimulate gonado-
tropin secretion, such as letrozole [40, 48] and human
chorionic gonadotropin (hCG) [44], stressful conditions
known to affect the hypothalamic-pituitary-ovarian axis,
such as chronic cold stress [42] and light exposure
[41, 47] and other drugs (D-galactose and valproic acid)
[43, 45]. All of these studies used rodent models: 4 used
mice [37, 39, 43, 46] and 8 had rats as the model organism
Table 2 Studies using drugs with estrogenic effects
Author, year [reference] Animal N Intervention Studied variables Results
Intervention period: Postnatal and puberty





↑ E2 ↓ androstenedione




































































Wistar rats 48 Estradiol valerate
Single dose















T testosterone, E2 estradiol, LH luteinizing hormone, FSH follicle-stimulating hormone, CL corpus luteum; ↑: increase; ↓ decrease; = equal
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[38, 40–42, 44, 45, 47, 48]. Intervention durations were
varied, with short-term, medium-term, and long-term treat-
ment all represented. The interventions were applied to an-
imals at distinct developmental stages, as described below.
Three studies described genetic modification at the
embryonic development stage, with generation of trans-
genic animals [37–39]. Two used mice as the model
organism [37, 39], while Shi et al. (2009) [38] used
female rats. Each study manipulated a different gene.
Risma et al. (1997) [37] used recombination of the LHβ
gene linked to the coding sequence of the carboxyl-
terminal peptide (CTP) of the hCG β-subunit, which
promotes increased LH and testosterone secretion as
well as polycystic ovaries. Devin et al. (2007) [39] gener-
ated a mouse that expresses human plasminogen activator
inhibitor-1 (PAI-1) to ascertain whether the increased
PAI-1 levels were associated with impaired ovulation. Shi
et al. (2009) [38] studied an obese transgenic mouse model
with leptin receptor dysfunction, and found increased
serum testosterone levels and atretic and cystic follicles.
Two studies described interventions in pubertal ani-
mals. Kafali et al. (2004) [40] exposed female mice to
three different doses of letrozole, a non-steroidal aroma-
tase inhibitor, whereas Kang at el. (2015) [47] exposed
the animals to continuous light for 16 weeks. Both stud-
ies found high testosterone levels and cystic follicles.
Table 3 Animal models of miscellaneous interventions
Author, year [reference] Animal N Intervention Variables studied Results
Intervention period: Embryonic
Risma et al. 1997 [37] Mouse 20 transgenic (bLHβ-CTP) Sexual hormones
Gonadotropin
Ovary morphology
↑ E2, ↑ T
↑ LH
↑ cystic follicles
Shi et al. 2009 [38] Rat 18 transgenic (JCR:LA-cp) Sexual hormones
Ovary morphology
↑ T = E2
↑ cystic follicles
↑ atretic follicles





















Bernuci et al. 2008 [42] Rat 17 Chronic cold stress +
LC lesion 60 days
Sexual hormones
Ovary morphology
↑ T ↑ E2,
= LH = FSH
↑ cystic follicles
↓ ovulation




Ota, et al. 1987 [44] Rat 33 hCG 80 days Sexual hormones
Gonadotropin
Ovary morphology
= T ↑ E2








= LH = FSH
Lagace &Nachtigal,
2003 [45]
Rat 22 Valproic acid 30 days Sexual hormones
Ovary morphology
= E2 = T
↑ replace cysts by cystic follicles
Radavelli- Bagatini et al.
2011 [46]
Mouse 45 Genetic Sexual hormones
Gonadotropin
Ovary morphology
↓ T ↑ E2
↓ LH
↓ CL, ↑ replace cysts by cystic follicles,
↑ atretic follicles
Li et al. 2016 [48] Rat 10 Letrozole Sexual hormones
Gonadotropin
Ovary morphology
↑ T, ↓ E2
↑ LH, ↑ FSH
↑ cystic follicles
T testosterone, E2 estradiol, LH luteinizing hormone, FSH follicle-stimulating hormone, CL corpus luteum; ↑: increase; ↓ decrease; = equal
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Seven studies described different interventions in adult
animals. Four used rats under short-term [45] or medium-
term treatment [41, 42, 44, 48]. Bernuci et al. (2008) [42]
demonstrated the role of the locus coeruleus (LC) in cold
stress-induced cystic follicles in rats. Ota et al. [44] re-
ported polycystic ovaries in mature rats under hCG stimu-
lation. Baldissera et al. (1991) [41] proposed a simple
experimental model for research into the pathophysiology
of polycystic ovaries based on continuous exposure to
light. Lagace and Nachtigal (2003) [45] exposed animals to
valproic acid (VPA), which was associated with the pres-
ence of ovarian cysts. Li et al. (2016) used Letrozole and
also observed cystic follicles and lower estrogen levels
[48]. All of these studies demonstrated an increased num-
ber of ovarian cysts, but only two [42] confirmed an in-
crease in testosterone levels. The other three studies
reported unchanged testosterone levels [44, 45] or did not
measure sex hormone levels [41].
Park and Choi (2012) [43] described a PCOS-like pheno-
type in a D-galactose-induced aging mouse model with a
medium-term observation period. Radavelli-Bagatini et al.
(2011) [46] studied a mouse strain known as the New
Zealand Obese (NZO), which naturally displays obesity,
insulin resistance, and a mild form of diabetes, manifes-
tations similar to those that often occur in women with
PCOS. Therefore, in this study, no supplementary
stimulus was used to test whether female NZO mice
present changes in ovarian morphology that could be
associated with metabolic abnormalities. Both studies
revealed ovarian morphological changes. Park and Choi
[43] reported increased testosterone levels and cystic
follicles, whereas Radavelli-Bagatini et al. (2011) [46]
demonstrated a high number of cysts and atretic
follicles.
Discussion
Animal models are regarded as valuable tools to investi-
gate pathophysiological processes of human diseases. In-
deed, in most cases, because of obvious ethical concerns,
some relevant queries cannot be answered by directly
studying affected patients. In PCOS, additional compli-
cating issues are its heterogeneous clinical presentation
and the fact that the etiology is still not well defined
[49]. Therefore, in the present review, we specifically se-
lected studies focusing on two main endocrine traits of
PCOS: ovarian morphology changes and circulating
levels of sex hormones and gonadotropins.
Reviews about animal models of PCOS have been
published previously, and have addressed various fea-
tures in different animal models of PCOS-like pheno-
types [14, 50–54]. However, this is the first systematic
review to provide a full list of rodents and non-human
primate models generated by distinct interventions, spe-
cifically focusing on two main reproductive features
present in women with PCOS: hyperandrogenism and
polycystic ovaries.
We included 39 experimental studies which used dis-
tinct procedures to induce PCOS-like models of ovarian
abnormalities and androgen excess, stratified into those
using androgens [10–28], estrogens and endocrine dis-
ruptors [27, 29–36], or other interventions [37–48].
Overall, there were broad differences among the studies
concerning hormonal interventions, animal species, and
developmental stage at the time of the experiments.
Most resulted in ovarian morphological changes, mainly
increases in the number of antral and cystic follicles and
decreases in the corpus luteum. However, while a hyper-
androgenic status could be induced by using androgens
[10–27] and other drugs [37–47] as stimulatory agents,
studies using drugs with estrogenic effect did not
measure androgen levels or did not observe changes in
circulating androgens [27, 29–36]. Therefore, hormonal
interventions using androgens seem to promote the
most consistent features of a PCOS-like phenotype in
animals, as previously suggested by Abbott et al. [49].
Among studies generating a hyperandrogenic state,
prenatal exposure of non-human primates to androgens
resulted in the most suitable animal model, displaying
both metabolic and reproductive characteristics of PCOS
[55, 56]. However, these models are expensive and are
not readily adaptable to genetic manipulation. In turn,
rodent models provide a versatile tool for investigating
biological mechanisms associated with the development
of PCOS. Among the advantages of using rodent species,
their stable genetic backgrounds, ease of handling and
maintenance, shorter reproductive lifespan, and short es-
trous cycles are the most important. However, some as-
pects that limit the use of rodents for investigation of
reproductive features should be taken into consideration.
First, rodents are polyovulatory, while women are mono-
ovulatory, suggesting that, despite similarities in the
hypothalamic-pituitary-ovarian axis, the FSH-dependent
follicle selection process in rodents differs from that in
women [57, 58]. Second, although the initial stages of
follicular growth (from primordial to preantral stage)
seem to be comparable between humans and rodents,
differences in regulation by intra-ovarian growth cannot
be ruled out [59]. Finally, there are marked differences
in the timing of onset of folliculogenesis between ro-
dents and women. While the primordial follicle pool and
initiation of follicle growth may arise during the later
stages of fetal development in humans, these processes
occur only during the early postnatal period in rodents
[60]. Thus, results obtained from mice and rats may not
translate directly to women.
Interestingly, differences in the generation of reproduct-
ive phenotypes are observed according to the developmen-
tal period in which androgen treatment is started [11]. In
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this sense, either starting testosterone treatment postnatally
[14–18] or administering DHT treatment during the pre-
pubertal period [19, 20] leads to the development of cyst-
like follicles. However, postnatal exposure to DHT results
in reprogramming of the hypothalamic-pituitary-ovarian-
axis [61]. Thus, comparisons between different inter-
vention models may be useful to define the timing of
reproductive PCOS phenotypes in experimental animal
models. One example is the study of Ota et al. [17], in
which, after treatment of 5-day-old female rats with a sin-
gle dose of testosterone propionate, various reproductive
characteristics of PCOS – such as cystic follicles, anovula-
tion, and imbalances in gonadotropins and sex hormones
– were later found over a 200-day observation period.
These results suggest androgen induction may have indir-
ectly promoted a pathologic elevation of FSH [17] that
blocked ovulation and induced cystic formation.
Estrogens and drugs with estrogenic effects have been
used to induce a PCOS-like syndrome in animals [52]
because of their ability to induce continuous estrus and
cystic follicles, with morphologic characteristics resem-
bling those observed in women. However, few studies
using these treatments have demonstrated high andro-
gen levels in blood. This was the case in a study in
which neonatal female rats were treated with the endo-
crine disruptor bisphenol A [32], and exhibited high tes-
tosterone levels and numerous cystic and atretic follicles
later in life. Possibly, acute exposure to estrogen could
lead to changes in follicular enzyme activity and subse-
quent suppression of androgen production by theca
cells. BPA is a potential agonist of endocrine estrogen,
acting differentially depending on tissue estrogen recep-
tor expression [62]. This suggests BPA could have less of
an effect on regulation of hypothalamic-pituitary-ovarian
axis negative feedback and, consequently, on ovarian
androgen secretion. Therefore, estrogen-induced inter-
vention may not be the optimal experimental models for
study of PCOS.
Other experimental interventions using external phys-
ical stressors have been reported to induce reproductive
features similar to the PCOS phenotype. Chronic cold
stress may produce such changes in ovarian morphology
by marked central activation of the sympathetic nerves
to the ovary [42]. Such activation by cold stress is prob-
ably mediated through a regulatory mechanism on the
hypothalamic-pituitary-adrenal axis by the locus coeru-
leus [42]. In addition, continuous light exposure could
lead to changes in the estrous cycle, such as continuous
estrous and cystic follicles, by altering the circadian
system [41].
Letrozole, an aromatase inhibitor, was another hormo-
nal intervention that induced high androgen levels and
ovarian cysts [40] by inhibiting androgen conversion to
estrogen and promoting alteration of the hypothalamic-
pituitary-gonadal axis and high LH levels. In addition, by
similar mechanisms, a transgenic mouse model success-
fully generated reproductive abnormalities by promoting
recombination of the LHβ gene and hCG β-subunit [37],
thus inducing chronic elevation of LH levels as well as
increased testosterone and estrogen levels and cystic
follicles.
Finally, although genetic rodent models cited in the
present review also fail to fully replicate the reproductive
phenotype of PCOS, the use of different transgenic
animals may be useful to identify potential pathways
involved in alterations in reproductive and endocrine
aspects in these animals, which, in turn, may lead to
important clinical insights into the etiology of human
PCOS.
One limitation of the present systematic review is that
we did not search for animal models related to the
metabolic abnormalities often associated with PCOS in
women. However, although insulin resistance is fre-
quently found in PCOS, it is not considered its primary
etiology. Another limitation is that we did not search for
studies using other animal species than rodents and
non-human primates, as these animals require no
unusual laboratory facilities. A third limitation is that we
did not perform meta-analysis, as the great heterogeneity
in animal species and experimental procedures pre-
cluded clustering of different studies to test the efficacy
of each model in producing the expected characteristics.
Conclusions
This systematic review included 39 reports of animal
models inducing two of the most characteristics features
of human PCOS: hyperandrogenism and ovarian morph-
ology changes. These studies used different experimental
procedures and model organisms. Although acute estra-
diol administration was associated with development of
cystic follicles, most of the studies were unable to dem-
onstrate testosterone overproduction. While other inter-
ventions, mainly transgenic animals, were able to induce
hyperandrogenism and cystic follicles, medium- or long-
term testosterone administration in the pre- and postna-
tal periods performed best for induction of a PCOS-like
phenotype, in rhesus macaque and rat models respect-
ively. In rats, postnatal exposure to androgens results in
reprogramming of the hypothalamic-pituitary-ovarian-
axis. Thus, comparisons between different intervention
models may be useful to define the timing of reproduct-
ive PCOS phenotypes in experimental animal models.
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